Survodutide

Survodutide is a dual GLP-1 and glucagon receptor agonist utilized primarily for weight management and the reversal of MASH/NASH. Users typically run daily subcutaneous doses ranging from 300 µg to 10 mg, with clinician-tier protocols centering on 6 mg daily over 4 to 12-week cycles. While nausea and GI distress are occasionally reported, injection-site reactions and fluid retention have not been a consistent theme in community feedback. Readers should note that the off-label evidence base for this substance remains thinner than current discourse suggests, as many exploratory indications lack published results.

Half-life~7 days

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.63.52.33.43.32.0

Research Evidence

Evidence shape

Survodutide possesses moderate clinical evidence, primarily supported by trials investigating obesity, NASH, and type 2 diabetes. While the research includes high-tier, blinded studies, the breadth of data remains narrow, with only three of the eight mapped indications yielding published results. The remaining registered trials are either exploratory, limited to pharmacokinetic assessments in healthy volunteers, or lack posted results, signaling that the current evidence base is concentrated in a few specific metabolic areas rather than broad clinical application.

Depthhow much
20 registered trials
16 completed · 3 with posted results · 4 recruiting / active · combined n=1095
Breadthhow many areas
9 indications mapped
3 with results · 5 thin / exploratory · 1 animal-only · 4 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
3 blinded with results · AE rows aggregated from 3 trials · 9 linked publications on registered trials
Breadth and depth22 rows captured
Human
direct clinical signal
21
Animal
translational support
1
In vitro
mechanistic support
0
HighMediumLow

Anecdotal efficacy

Survodutide side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Badgercompounds
US
10 mg
$22.99
$2.3/mg
2
Prism Aminos
US
10 mg
$24.25
$2.42/mg
3
Mrbeetoe
--
50 mg
$150.00
$3/mg
4
Bulk Peptide Supply
unknown
100 mg×10
$350.00
$3.5/mg
5
HKRoids
Hong Kong
100 mg×10
$409.00
$4.09/mg
6
Elite Aminos LLC
--
20 mg
$95.00
$4.75/mg

price offers can be sorted by column

1-6 of 48

SURVODUTIDE dosing & protocol

How SURVODUTIDE is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 17
Typical dose
2.4 mg300 µg – 3.6 mg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 6 reported doses · darker = more
Frequency
weekly
Route
subQ

In the reported research trials, SURVODUTIDE was administered subcutaneously on a weekly basis, with doses ranging from 0.3 mg to 3.6 mg and a typical dose of 2.4 mg per injection; no specific cycling regimen was described.

17 sources
Clinician practice
Doctor & published-protocol guidance · n = 2
Typical dose
6 mg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 2 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
subQ

In the clinician tier, sources cite a dose of 6 mg subcutaneously, with one reporting daily administration and another weekly administration. No cycling schedule is specified.

2 sources
Anecdotal
Community-reported real-world use · n = 11
Typical dose
10 mg300 µg – 10 mg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 14 reported doses · darker = more
Frequency
unspecified
Route
subQ

Community reports subcutaneous doses ranging from 300 mcg to 10 mg, with a typical reported dose of 10 mg; dosing frequency is not specified.

11 sources

Related peptides

SemaglutideTirzepatideRetatrutideAOD-9604CagrilintideOrforglipronLiraglutideExenatideTesamorelinEloralintideTesofensineMazdutide